N/A
N=32
Effects of UC-II, Glucosamine and Curcumin Supplementation on Knee Pain and Inflammation.
Inflammation · Knee Pain Chronic
Bottom Line
View on ClinicalTrials.gov: NCT06581094 ↗Enrolled (actual)
32
Serious AEs
—
Results posted
Jan 2026
Primary outcome: Primary: Points Change of Pain Evaluation Scale — 1.49; 1.15; 1.15; 1.14 score on a scale — p=0.478
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- UCII, glucosamine and curcumin (Dietary_supplement); Placebo (Dietary_supplement)
- Age
- Adult, Older Adult · 20+ yrs
- Sex
- All
- Sponsor
- Taipei Medical University
- Primary completion
- Nov 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Points Change of Pain Evaluation Scale |
1.49; 1.15; 1.15; 1.14; 0.85; 0.50 | 0.478 |
| PRIMARY Time Change of Up-and-go Test |
9.96; 9.3; 8.75; 8.83; 8.64; 8.55 | 0.399 |
| PRIMARY Degrees Change of Range of Motion (ROM) |
141.73; 137.67; 141.20; 140.80; 137.93; 136.80 | 0.502 |
| PRIMARY Points Change of Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) |
5.73; 5.27; 4.47; 4.73; 4.07; 3.67 | 0.823 |
| PRIMARY The Concentration of Serum Inflammatory Factors |
NA; NA; NA; NA; NA; NA | — |
Summary
This research evaluated the effects of UCII, glucosamine and curcumin supplementation on knee pain and inflammation.
Eligibility Criteria
Inclusion Criteria
- Knee plain
Exclusion Criteria
- Severe diseases of the heart, liver, kidneys, endocrine system, and other organs
- Long-term use of medication
- Infection, hypertension, diabetes, cerebrovascular disease, heart disease, liver disease, kidney disease, gastrointestinal disease
- Allergy to this product
Data sourced from ClinicalTrials.gov (NCT06581094). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.